Trial Profile
Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2022
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Ferrous fumarate
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FIT
- 02 Aug 2022 According to a CSL Vifor media release, Vifor Pharma has been acquired by CSL and renamed to CSL Vifor.
- 27 Aug 2018 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
- 27 Aug 2018 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2019.